Evidence map›Paper›PMID 38228169›Full record

ArticleOpen biology2024

Formation of amyloid fibrils by the regulatory 14-3-3

Darius Šulskis, Mantas Žiaunys, Andrius Sakalauskas, Rūta Sniečkutė, Vytautas Smirnovas

Open access · goldAbstract read
In one paragraph

Article in Open biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Darius ŠulskisInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID 0000-0002-6925-4469
Mantas ŽiaunysInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Andrius SakalauskasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Rūta SniečkutėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Vytautas SmirnovasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Vilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 14-3-3 proteins are a highly conserved adaptor protein family with multi-layer functions, abundantly expressed in the brain. The 14-3-3 proteins modulate phosphorylation, regulate enzymatic activity and can act as chaperones. Most importantly, they play an important role in various neurodegenerative disorders due to their vast interaction partners. Particularly, the 14-3-3

Indexed as

Neurodegenerative DiseasesParkinson Disease14-3-3 Proteinsalpha-SynucleinAmyloidAmyloid beta-PeptidesHumans14-3-3 Proteinsalpha-SynucleinAmyloidAmyloid beta-Peptides14-3-3ζamyloidfibrilsα-synuclein

Identifiers

PMID38228169
PMCPMC10791532
OpenAlexW4390929426

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.